Tafamidis Meglumine API

Mechanism of Action

Tafamidis Meglumine is a drug used to treat transthyretin (TTR) amyloidosis, a rare genetic disease characterized by the buildup of abnormal proteins in various tissues and organs, including the heart, peripheral nerves, and eyes.

The mechanism of action of Tafamidis Meglumine is based on its ability to stabilize the TTR tetramer, which is the native form of the protein. Tafamidis Meglumine binds to the TTR protein and prevents it from undergoing a conformational change that would normally lead to its aggregation and formation of amyloid fibrils. By stabilizing the TTR tetramer, Tafamidis Meglumine slows down the progression of TTR amyloidosis and helps to preserve the function of affected tissues and organs.

In addition, Tafamidis Meglumine has been shown to have an anti-inflammatory effect, which may also contribute to its therapeutic effects in TTR amyloidosis.

Indication

Tafamidis Meglumine is a medication used to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a type of heart disease caused by buildup of amyloid deposits in the heart. It works by stabilizing the transthyretin protein, which helps to prevent the formation of amyloid deposits and slow the progression of heart damage.

Tafamidis Meglumine is indicated for the treatment of transthyretin amyloid cardiomyopathy in adult patients with stage F2 or F3 cardiac symptoms (based on the New York Heart Association [NYHA] functional classification).

It is important to note that Tafamidis Meglumine is not a cure for transthyretin amyloid cardiomyopathy, but it can help to slow the progression of the disease and improve symptoms in some patients.

Dr. Reddy’sの専門知識・技術

ハイデラバード（インド）に本社を構えるDr. Reddy’s Laboratoriesは、世界的に有名な原薬（API）供給業者です。Dr. Reddy’sのAPIビジネスは米国、ヨーロッパ、ブラジル、南米、日本、中国、韓国、その他の新興市場において製薬会社の推奨パートナーとなっています。

Dr. Reddy’sのAPIビジネスは、ステロイド、ペプチド、複合長鎖分子、高薬理活性API（HPAPI /腫瘍学薬）など、複合APIの開発・製造において、30年以上にわたり高度な技術的実績を築き上げ、成長しています。この専門知識・技術は弊社の知的財産および規制関連業務の実績と共に、一貫して規制基準を満たし、それを超える優れた価値を生み出しています。Dr. Reddyの(-) API, R&D (研究開発)、IP、規制の高度な専門知識・技能の結果です。

顧客が真っ先に市場に参入するのに重要な要素は、機敏な供給網です。弊社は全施設を効率的に、そしてコストを最適化して稼働させ、品質と安全性、また、生産性の最新基準に従うことで、そうした供給網を実現させます。オフィスと工場の結びつきを強化し、ダイナミックな市場の変化に迅速に対応しています。そうした理由から、弊社は不足を解消して突発的な供給を満たすことができるのです。